ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Unilife Corporation (UNIS) Report Updated: Apr 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Unilife Corporation (UNIS)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Health Care Equipment & Supplies
Competitors: ATRI, ANIK, DHRM, LMAT

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: C down downgrade
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

Unilife Corporation© quotemedia

Company Profile

Unilife Corporation designs, develops, manufactures, and commercializes injectable drug delivery systems in the United States and internationally. The company’s principal product is the Unifill ready-to-fill syringe, which is designed for pharmaceutical manufacturers in a ready form for filling with their injectable drugs and vaccines. It also offers Unifill Syringe, a staked (fixed) retracting needle that is designed for use with liquid stable drugs; Unifill Select glass prefilled syringe, which facilitates the use of liquid stable drug or vaccine, or a diluent to reconstitute and deliver a lyophilized drug supplied in a vial; and Unitract 1mL syringes for use in healthcare facilities and by patients who self-administer prescription medication, such as insulin. In addition, the company provides Rita disposable auto-injector that is designed to inject the prefilled dose from a single Unifill syringe; and Lisa reusable auto-injector, which automates the removal of the needle shield and enhances needle insertion and retraction, as well as EZMix dual or multi-chamber prefilled syringe for the reconstitution and delivery of injectable therapies. Further, it offers the Precision-Therapy range of bolus injectors for use with bolus-based therapies that require short or long duration injections; and the Flex-Therapy range of bolus injectors for use with rate-based therapies that require infusion over a longer duration of time where the delivery rate is controlled for hours or days. Additionally, the company provides specialized device technology platforms comprising devices for targeted organ delivery, low dose delivery systems, and implant deployment systems for the administration of an implantable drug through an intravitreal or intraocular injection. Its customers also include pharmaceutical and biotechnology companies; and suppliers of combination drug-delivery devices to government agencies. The company is headquartered in York, Pennsylvania.

Recent News: Unilife Corporation